"We know we have the tiger by the tail and now there is a significant amount of demand for this product. We think this is very good, positive data from Phase II."

— Hoji Alimi, CEO and founder of Oculus Innovative Sciences, discussing the company's development of a gel-based version of its wound treatment product based on Microcyn Technology, "Oculus cuts costs in advance of U.S. launch of Microcyn," pp. 2, 10.

No Comments